ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.758,17
0,27%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08747
0,00%
Bitcoin
66.927,82
1,16%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Minerva Neurosciences Inc (NERV)

  7. Minerva Neurosciences Inc (NERV) News

NERV

Minerva Neurosciences (NERV)

Minerva Neurosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NERV
DatumZeitQuelleÜberschriftSymbolFirma
01/05/202413h30GlobeNewswire Inc.Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
27/02/202414h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
27/02/202414h00GlobeNewswire Inc.Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
22/02/202413h00GlobeNewswire Inc.Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
22/02/202412h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NERVMinerva Neurosciences Inc
07/11/202313h30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
07/11/202313h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
05/10/202322h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
05/10/202322h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
29/09/202314h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
29/09/202314h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
28/09/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
15/08/202315h28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NERVMinerva Neurosciences Inc
15/08/202315h26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NERVMinerva Neurosciences Inc
15/08/202315h25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NERVMinerva Neurosciences Inc
10/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NERVMinerva Neurosciences Inc
09/08/202323h12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NERVMinerva Neurosciences Inc
04/08/202314h07Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NERVMinerva Neurosciences Inc
01/08/202313h30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
01/08/202313h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
07/07/202322h18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NERVMinerva Neurosciences Inc
03/07/202322h04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NERVMinerva Neurosciences Inc
28/06/202314h38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
28/06/202314h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
28/06/202314h30GlobeNewswire Inc.Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketNASDAQ:NERVMinerva Neurosciences Inc
20/06/202314h41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
15/05/202313h30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
15/05/202313h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NERVMinerva Neurosciences Inc
10/05/202314h00GlobeNewswire Inc.Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
08/05/202314h30GlobeNewswire Inc.Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023NASDAQ:NERVMinerva Neurosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NERV

Kürzlich von Ihnen besucht

TG
BRH
Berkshire Hathaway A Dl 5
TG
LTP
Ltc Properties
TG
6H4
Invictus Energy
TG
PJZ
APA
USOTC
FMCB
Farmers and Merchants Ba... (QX)
NYSE
AGRO
Adecoagro
NYSE
LQU
Quilmes Ind Quinsa
NYSE
STZB
Constellation
NYSE
BFB
Brown Forman
NYSE
MKCV
Mccormick
AMEX
SEB
Seaboard
NYSE
BFA
BrownForman
AMEX
ALN
NYSE
THS
Treehouse Foods
NYSE
INGR
Ingredion
ASX
CAVO
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten